Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Brachytelephalangic chondrodysplasia punctata (BCDP) is a form of nonrhizomelic chondrodysplasia punctata, a primary bone dysplasia, characterized by hypoplasia of the distal phalanges of the fingers, nasal hypoplasia, epiphyseal stippling appearing in the first year of life, and mild and nonrhizomelic shortness of the long bones.
Features include: Microcephaly, Hearing loss (hearing impairment), Short nasal septum, and Short stature and 10 more.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 2 | Global developmental delay, Depressed nasal bridge |
Head and neck | 1 | Microcephaly |
Ears | 1 | Hearing loss (hearing impairment) |
Growth and development | 1 | Short stature |
Skin | 1 | Dry, scaly skin (ichthyosis) |
Eyes | 1 | Cataract |
Bones and joints | 1 | Abnormality of the vertebral column |
Arms and legs | 1 | Short distal phalanx of finger |
Hormones | 1 | Hypogonadism |
Affected Males The most consistent clinical features of X-linked chondrodysplasia punctata 1 (CDPX1) in affected males are chondrodysplasia punctata (CDP), brachytelephalangy, and nasomaxillary hypoplasia. Most affected males have minimal morbidity, and skeletal findings improve by adulthood; however, some have significant medical problems including airway stenosis and cervical spine instability. To date, approximately 50 individuals with a pathogenic variant in ARSL have been reported in the literature. The following description of the phenotypic features associated with this condition is based on the case series from and . Table 2. Chondrodysplasia Punctata 1, X-Linked: Frequency of Select Features
Feature | Proportion of Persons w/Feature1 | Comment |
|---|---|---|
Chondrodysplasia punctata (CDP) | 45/462 | CDP typically not visible on radiographs after age 3 yrs |
ARSL encodes arylsulfatase L (589 aa). Exhibits arylsulfatase activity towards the artificial substrate 4-methylumbelliferyl sulfate. May be essential for the correct composition of cartilage and bone matrix during development. Highest expression in Pancreas (26.2 TPM) and Liver (20.9 TPM).
X-linked chondrodysplasia punctata 1 is caused by mutations in the ARSL gene on chromosome X.
ARSL is classified as a druggable target (Druggable Genome category) with score 1.4.
No genotype-phenotype correlations have been identified.
Source: GeneReviews — "Chondrodysplasia Punctata 1, X-Linked"
Penetrance may be incomplete. ARSL pathogenic variant was identified in an affected proband and his unaffected maternal grandfather . A deletion of exons 7-10 was identified in an affected proband and his asymptomatic maternal grandfather . Considering that physical features of CDPX1 improve with age, it is uncertain whether such instances represent non-penetrance.
Source: GeneReviews — "Chondrodysplasia Punctata 1, X-Linked"
X-linked chondrodysplasia punctata 1 (CDPX1) should be suspected in a male proband with the following clinical and radiographic findings.
Clinical findings
Brachytelephalangy (shortening of the distal phalanges)
Nasomaxillary hypoplasia
Hypoplasia of the anterior nasal spine
Flattened nasal base
Reduced nasal tip protrusion with short columella
Crescent-shaped nostrils
Vertical grooves within the alae nasi (in some individuals)
Postnatal short stature
Radiographic findings
Source: GeneReviews — "Chondrodysplasia Punctata 1, X-Linked"
Genetic Disorders
Table 3a.
Disorders with Brachytelephalangic Chondrodysplasia Punctata (BCDP) in the Differential Diagnosis of CDPX1
Gene(s) | Disorder | MOI | Additional Overlapping Feature | Findings Distinguishing the Disorder from CDPX1
GGCX
| Combined deficiency of vitamin K-dependent clotting factor 1 (OMIM 277450) factor 2 (OMIM 607473) | AR | Nasal hypoplasia | Bleeding disorder due to variably levels of coagulation factors II, VII, IX, X, protein C, protein S, protein Z
MGP | Keutel syndrome (OMIM 245150) | AR | More diffuse progressive calcification of cartilage incl nose, auricles, respiratory tract
AR = autosomal recessive; CDPX1 = chondrodysplasia punctata 1, X-linked; MOI = mode of inheritance
Table 3b.
Source: GeneReviews — "Chondrodysplasia Punctata 1, X-Linked"
Genetic testing for ARSL is available. Testing is considered confirmatory for diagnosis.
No approved treatments are currently available for X-linked chondrodysplasia punctata 1. The disease remains an area of unmet medical need.
Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with X-linked chondrodysplasia punctata 1 (CDPX1), the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended. Table 4. Recommended Evaluations Following Initial Diagnosis in Individuals with Chondrodysplasia Punctata 1, X-Linked
System/Concern | Evaluation | Comment |
|---|---|---|
Respiratory | Assessment of upper lower airways by ENT pulmonologist | If stridor is present Obstructive sleep |
apnea | Polysomnography | If sleep apnea is suspected Skeletal |
instability | Flexion, neutral, extension lateral radiographs of the cervical spine | Cervical spine MRI if clinical evidence of cervical myelopathy or significant instability on radiographs; Special consideration when performing this study in flexion extension positions as spinal cord compression may only occur w/these movements (i.e. |
Audiology | Hearing assessment | To assess for sensorineural conductive hearing loss |
Developmental delay | Developmental assessment | Ophthalmologic |
Source: GeneReviews — "Chondrodysplasia Punctata 1, X-Linked"
In individuals with cervical spine instability, extreme neck extension and neck flexion and contact sports should be avoided. In case of general anesthesia, the cervical spine should be assessed by imaging prior to the procedure.
Source: GeneReviews — "Chondrodysplasia Punctata 1, X-Linked"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "Chondrodysplasia Punctata 1, X-Linked"
View trials for X-linked chondrodysplasia punctata 1
Table 6. Recommended Surveillance for Individuals with Chondrodysplasia Punctata 1, X-Linked
System/Concern | Evaluation | Frequency |
|---|---|---|
Short stature | Growth assessment | Annually |
Scoliosis | Clinical assessment of thoracic lumbar spine | As needed Cervical spine instability |
Hearing loss | Hearing assessment | As needed Developmental delay |
Source: GeneReviews — "Chondrodysplasia Punctata 1, X-Linked"
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for X-linked chondrodysplasia punctata 1.
4 publications have been identified in PubMed for X-linked chondrodysplasia punctata 1. Research spans Review / Meta-Analysis (75%) and Case Report / Case Series (25%).
Samuels M (2025). [PMID: 39908167](https://pubmed.ncbi.nlm.nih.gov/39908167/). *Molecular genetics & genomic medicine*. [Case Report / Case Series]
Broeren E (2024). [PMID: 39313411](https://pubmed.ncbi.nlm.nih.gov/39313411/). *Prenatal diagnosis*. [Review / Meta-Analysis]
Bosco M (2024). [PMID: 39181504](https://pubmed.ncbi.nlm.nih.gov/39181504/). *Journal of gynecology obstetrics and human reproduction*. [Review / Meta-Analysis]
Zhou L (2024). [PMID: 39425194](https://pubmed.ncbi.nlm.nih.gov/39425194/). *BMC medical genomics*. [Review / Meta-Analysis]
Data assembled from 8 of 12 sources · Last updated Sep 19, 2026, 3:30 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about X-linked chondrodysplasia punctata 1
42/42 |
— |
Brachytelephalangy | 33/35 | — |
Short stature (height 5th %ile) | 12/16 | Postnatal onset |
Significant respiratory abnormalities | 17/23 | Frequent respiratory infections, asthma, central apnea, tachypnea, neonatal respiratory distress, mechanical ventilation, tracheotomy, chronic nasal obstruction, nasal stents |
Mixed conductive sensorineural hearing loss | 13/18 | — |
Significant cervical spine abnormalities | 10/16 | Dysplasia or hypoplasia of cervical vertebrae, C1–C2 anterior subluxation, kyphosis, cervical cord compression, spinal canal stenosis |
Delayed cognitive development | 5/6 | 1. From , . Note: These studies may have an ascertainment bias towards more severely affected children. A child with brachytelephalangy, nasomaxillary hypoplasia, and tracheobronchial calcifications did not have CDP at age 14 months . Nasomaxillary hypoplasia. |
Source: GeneReviews — "Chondrodysplasia Punctata 1, X-Linked"
abnormalities |
Ophthalmologic eval |
To evaluate for cataracts, optic disc atrophy, small optic nerves |
Cardiac anomalies | Echocardiogram | To evaluate for patent ductus arteriosus, ventricular septal defect, atrial septal defect, pulmonary artery stenosis |
Genetic counseling | By genetics professionals2 | To inform affected persons families re nature, MOI, implications of CDPX1 in order to facilitate medical personal decision making Family support resources |